GeoVax Labs CEO to Present at 37th Annual Roth Conference on Immunotherapies and Vaccines
GeoVax Labs CEO David Dodd to present at 37th Annual Roth Conference on March 17, 2025, showcasing the company's innovative immunotherapies and vaccines. Learn about GeoVax's lead clinical program for a COVID-19 vaccine and its impact on the biotechnology industry.
This news highlights GeoVax's advancements in developing vaccines against infectious diseases and cancers, including a next-generation COVID-19 vaccine. Investors and stakeholders in the biotechnology and healthcare industries should pay attention to GeoVax's presentation at the conference.